Angioimmunoblastic T-cell lymphoma primary prevention: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Angioimmunoblastic T-cell lymphoma}} | {{Angioimmunoblastic T-cell lymphoma}} | ||
{{CMG}}; {{AE}}{{Sab}} | |||
==Overview== | |||
There are no established measures for the primary prevention of angioimmunoblastic T-cell lymphoma. | |||
==Primary Prevention== | |||
There are no established measures for the primary prevention of angioimmunoblastic T-cell lymphoma. | |||
==References== | ==References== |
Latest revision as of 21:50, 15 April 2019
Angioimmunoblastic T-cell lymphoma Microchapters |
Differentiating Angioimmunoblastic T-cell lymphoma from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Angioimmunoblastic T-cell lymphoma primary prevention On the Web |
American Roentgen Ray Society Images of Angioimmunoblastic T-cell lymphoma primary prevention |
FDA on Angioimmunoblastic T-cell lymphoma primary prevention |
CDC on Angioimmunoblastic T-cell lymphoma primary prevention |
Angioimmunoblastic T-cell lymphoma primary prevention in the news |
Blogs on Angioimmunoblastic T-cell lymphoma primary prevention |
Directions to Hospitals Treating Angioimmunoblastic T-cell lymphoma |
Risk calculators and risk factors for Angioimmunoblastic T-cell lymphoma primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sabawoon Mirwais, M.B.B.S, M.D.[2]
Overview
There are no established measures for the primary prevention of angioimmunoblastic T-cell lymphoma.
Primary Prevention
There are no established measures for the primary prevention of angioimmunoblastic T-cell lymphoma.
References